NCT02605954: A reported trial by Gilead Sciences
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02605954 |
|---|---|
| Title | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adult Subjects |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 18, 2015 |
| Completion date | June 14, 2017 |
| Required reporting date | June 14, 2018, midnight |
| Actual reporting date | June 13, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |